H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sorrento Therapeutics (NASDAQ:SRNE) on Monday, setting a price target of $26, which is approximately 337.71% above...
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sorrento Therapeutics (NASDAQ:SRNE) on Monday, setting a price target of $26, which is approximately 304.98% above...
Stocks advanced yesterday, with the S&P 500’s last minutes pushing higher to close at 3,915. The index was fairly well-contained, trading below 3,910 all day with buyers...
As the world eagerly awaits results for the U.S. Presidential election, there's yet another highly anticipated event: a breakthrough in the coronavirus vaccine. Positive news about...
Sorrento Therapeutics (NASDAQ:SRNE) emerged as an early contender in the fight against COVID-19 and fast cementing its position. The company has multiple vaccine and therapy...
Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The Company is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.